Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.44Last Year’s EPS
-1.07Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: -7.19%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical and financial advancements, including the successful commencement of key trials and a strengthened financial position. However, challenges remain, particularly in educating the target patient population for avexitide.Company Guidance
During the first quarter 2025 earnings call, Amylyx Pharmaceuticals provided detailed guidance on their ongoing clinical programs and financial position. The company highlighted that they dosed the first participant in the Phase 3 LUCIDITY trial for avexitide, aimed at treating post-bariatric hypoglycemia (PBH), a condition affecting approximately 160,000 individuals in the U.S. They anticipate enrollment completion by 2025 and expect top-line data in the first half of 2026, with a potential commercial launch in 2027. Additionally, Amylyx advanced their Phase 1 LUMINA trial of AMX0114 for ALS and the Phase 2b ORION trial for progressive supranuclear palsy (PSP), with data expected in the third quarter of 2025. Financially, the company raised approximately $65.5 million, boosting their cash position to $204.1 million, which extends their anticipated cash runway through the end of 2026. Operating expenses for the quarter were $37.8 million, down 82% from Q1 2024, with research and development costs at $22.1 million and selling, general, and administrative expenses at $15.7 million.Successful Dosing in Key Clinical Trials
First participants were dosed in the pivotal Phase 3 LUCIDITY clinical trial of avexitide for post-bariatric hypoglycemia and in the Phase 1 LUMINA trial of AMX0114 for ALS.
Financial Position Strengthened
Raised approximately $65.5 million, extending cash runway through the end of 2026. Ended the quarter with a cash position of $204.1 million.
Progress in Clinical Programs
Reported positive top-line data from the Phase 2 HELIOS trial for Wolfram syndrome. Enrollment completed for the Phase 2b ORION trial in PSP.
FDA Breakthrough Therapy Designation
Avexitide received FDA breakthrough therapy designation for post-bariatric hypoglycemia, highlighting its potential impact.
Decrease in Operating Expenses
Total operating expenses for the quarter were $37.8 million, down 82% from the same period in 2024.
---
AMLX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AMLX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $4.87 | $4.58 | -5.95% |
Mar 04, 2025 | $3.00 | $3.01 | +0.33% |
Nov 07, 2024 | $6.22 | $6.54 | +5.14% |
Aug 08, 2024 | $1.88 | $1.80 | -4.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Amylyx Pharmaceuticals Inc (AMLX) report earnings?
Amylyx Pharmaceuticals Inc (AMLX) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Amylyx Pharmaceuticals Inc (AMLX) earnings time?
Amylyx Pharmaceuticals Inc (AMLX) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AMLX EPS forecast?
AMLX EPS forecast for the fiscal quarter 2025 (Q2) is -0.44.
---
